中国药理学通报2016，Vol.32Issue(5)：607-611,612,6.DOI:10.3969/j.issn.1001-1978.2016.05.004
以芳香烃受体为药物靶点的肿瘤治疗研究
Anti-tumor therapy for targeting aryl hydrocarbon receptor
摘要
Abstract
Aryl hydrocarbon receptor ( AhR) is a ligand-depend-ent transcription factor that mediates the toxicity of xenobiotic ligands like 2,3,7,8-tetrachlorodibenzo-p-dioxins(TCDDs). AhR influences tumor growth, survival, migration and invasion by regulating proliferation, apoptosis and immune metabolism of tumor cells. AhR has two ways to regulate tumor development, and ligands like polycyclic aromatic hydrocarbons( PAHs) , hal-ogenated aromatic hydrocarbons( HAHs) can induce tumorigene-sis. However, some compounds such as benzothiazole and amin-oflavone can activate AhR, which suppresses the tumor progres-sion and suggests that AhR may be a novel drug target for anti-tumor therapy. The paper discussed the role of AhR in tumori-genesis, the mechanism of the drugs targetting AhR and the sta-tus of studying AhR as a potential target in anticancer therapy.关键词
芳香烃受体/肿瘤/配体/靶向药物/作用机制/研究现状Key words
aryl hydrocarbon receptor/tumor/ligand/targeted drugs/mechanism/present state分类
医药卫生引用本文复制引用
刘颖,张洪英,唐涛,刘飞飞,吴谓,罗瑛,张继虹..以芳香烃受体为药物靶点的肿瘤治疗研究[J].中国药理学通报,2016,32(5):607-611,612,6.基金项目
国家自然科学基金资助项目( No 81260501) （ No 81260501）
云南省应用基础研究计划项目(No 2014FD011) （No 2014FD011）
